Cantor Fitzgerald Reiterates Overweight on Aurinia Pharmaceuticals, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated an Overweight rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) and maintained a $10 price target.
September 09, 2024 | 3:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating for Aurinia Pharmaceuticals, maintaining a $10 price target, indicating confidence in the company's potential.
The reiteration of an Overweight rating and maintenance of a $10 price target by Cantor Fitzgerald suggests a positive outlook for Aurinia Pharmaceuticals, likely boosting investor confidence and potentially leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100